No significant impact was found regarding PAPR inhibitor resistance in the PEO4 cell line (Figure S4C-D), although it has suggested that PPP2R2A KD leads to increased sensitivity to PARPi in NSCLC 31. Here, PPP2R2A is linked to non-small cell lung carcinoma.